Phase I study of mitonafide with a 3-day administration schedule: Early interruption due to severe central nervous system toxicity
- 1 December 1994
- journal article
- clinical trial
- Published by Springer Nature in Investigational New Drugs
- Vol. 12 (4) , 277-281
Abstract
Eleven patients with solid tumors for whom effective therapy was not available entered a phase I study of mitonafide given as a short intravenous (i.v.) infusion daily for 3 consecutive days. The initial dose level was selected according to the experience from another phase I study using a 5-day administration schedule. Six patients entered the first dose level (180 mg/m2/day × 3 days) and 4 of them had grade 3–4 leukopenia. This level was considered to be the maximum tolerated dose (MTD) and no further dose escalations were attempted. The following 5 patients received a dose approximately 10% inferior to the previous one (160 mg/ m2/day × 3 days). Three of them had grade 3–4 neutropenia. Three partial responses were observed in total. After inclusion of 11 patients, an unexpected toxicity, central nervous system (CNS) toxicity, consisting of severe loss of memory, temporospatial disorientation and high integrative function impairment was observed in 5 patients (46%). A median patients' follow-up of 3 months after treatment discontinuation showed that these alterations were progressive and not reversible. This disabling toxicity prompted us to an early study interruption. In conclusion, mitonafide, when administered as a short 3-day i.v. infusion, can induce severe and irreversible CNS toxicity. Nevertheless, since antitumor activity has been observed, further development of the drug is recommended with different schedules of administration that have shown not to produce neurotoxicity,i.e., 5-day continuous infusion.Keywords
This publication has 9 references indexed in Scilit:
- Phase I study of mitonafide in solid tumorsInvestigational New Drugs, 1992
- Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancerInvestigational New Drugs, 1992
- Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs.Molecular Pharmacology, 1989
- Grading of neurotoxicity in cancer therapy.Journal of Clinical Oncology, 1986
- Mechanism of DNA strand breaks by mitonafide, an imide derivative of 3-nitro-1,8-naphthalic acidBiochemical Pharmacology, 1985
- Reporting results of cancer treatmentCancer, 1981
- Synthesis and mode(s) of action of a new series of imide derivatives of 3-nitro-1,8 naphthalic acidCancer Chemotherapy and Pharmacology, 1980
- Intercalative binding to DNA of antitumour drugs derived from 3-nitro-1,8-naphthalic acidNucleic Acids Research, 1979
- “Mini-mental state”Journal of Psychiatric Research, 1975